HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Andres, P. L. Articles by Munsat, T. L. Search for Related Content PubMed PubMed Citation Articles by Andres, P. L. Articles by Munsat, T. L.

Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis

From the Neuromuscular Research Unit, Department of Neurology, Tufts-New England Medical Center, Boston, MA. Funded by grants from the Muscular Dystrophy Association and NIH Grants/GCRC# MO1RR00054 and RO1NS24623. Received January 30, 1987. Accepted for publication in final form June 26, 1987.

The Tufts Quantitative Neuromuscular Exam (TQNE) consists of 28 items that were designed to measure voluntary motor deficit in amyotrophic lateral sclerosis (ALS) and related diseases. Individual raw data were converted to Z scores for standardization and then grouped into five megascores with statistical and clinical relevance. The derived megascores were Mega 1, pulmonary function; Mega 2, bulbar function; Mega 3, timed hand activities; Mega 4, isometric arm strength; and Mega 5, isometric leg strength. Megascores should enhance the usefulness of testing in therapeutic trials and in analyzing the natural history of ALS and related diseases.

Address correspondence and reprint requests to Ms. Andres, Box 273, Neuromuscular Research Unit, New England Medical Center, 750 Washington Street, Boston, MA 02111.

This article has been cited by other articles:

				F. Deymeer, P. Serdaroglu, Y. Parman, and M. Poda Natural history of SMA IIIb: Muscle strength decreases in a predictable sequence and magnitude Neurology, August 26, 2008; 71(9): 644 - 649. [Abstract] [Full Text] [PDF]

				B. J. Traynor, H. Zhang, J. M. Shefner, D. Schoenfeld, M. E. Cudkowicz, and on behalf of the NEALS Consortium Functional outcome measures as clinical trial endpoints in ALS Neurology, November 23, 2004; 63(10): 1933 - 1935. [Abstract] [Full Text] [PDF]

				P. N. Leigh and H. Mitsumoto MMT vs MVIC: Low-tech scores high? Neurology, December 9, 2003; 61(11): 1472 - 1473. [Full Text] [PDF]

				Great Lakes ALS Study Group A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis Neurology, December 9, 2003; 61(11): 1503 - 1507. [Abstract] [Full Text] [PDF]

				S. B. Rutkove, R. A. Parker, R. A. Nardin, C. E. Connolly, K. J. Felice, and E. M. Raynor A pilot randomized trial of oxandrolone in inclusion body myositis Neurology, April 9, 2002; 58(7): 1081 - 1087. [Abstract] [Full Text] [PDF]

				G. A. R. Mealing, T. H. Lanthorn, D. L. Small, R. J. Murray, K. C. Mattes, T. M. Comas, and P. Morley Structural Modifications to an N-Methyl-D-aspartate Receptor Antagonist Result in Large Differences in Trapping Block J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 906 - 914. [Abstract] [Full Text]

				M. C. Dalakas, B. Koffman, M. Fujii, S. Spector, K. Sivakumar, and E. Cupler A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM Neurology, February 13, 2001; 56(3): 323 - 327. [Abstract] [Full Text] [PDF]

				S. T. Iannaccone, B. S. Russman, R. H. Browne, C. R. Buncher, M. White, and F. J. Samaha Prospective Analysis of Strength in Spinal Muscular Atrophy J Child Neurol, February 1, 2000; 15(2): 97 - 101. [Abstract] [PDF]